July 7, 2009Open Access

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

Key Points

Key points are not available for this paper at this time.

Abstract

Neither GEM FDR nor GEMOX resulted in substantially improved survival or symptom benefit over standard GEM in patients with advanced pancreatic cancer.

KI fragen

Bookmark

View Full Paper

Cite This Study

Poplin et al. (Tue,) studied this question.

synapsesocial.com/papers/69d7cd4e319e71454dbedaaf https://doi.org/https://doi.org/10.1200/jco.2008.20.9007

KI fragen

Bookmark

View Full Paper